Results 121 to 130 of about 1,158 (177)

Three-year experience with GLP-2 analog in intestinal rehabilitation for pediatric-onset short bowel syndrome. [PDF]

Pediatr Surg Int
Tazuke Y, Kimura T, Ueno T, Nakahata K, Deguchi K, Uga N, Okuyama H, Oue T.   +7 more
europepmc   +1 more source

Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms.

J Clin Endocrinol Metab
Auernhammer CJ, Wang K, Maccio U, Knösel T, Hungbauer MP, Schilbach K, Maurer J, Peischer L, Reul A, Kuzmenko E, Luca E, Hamati J, Vetter D, Oberholzer J, Fritsch R, Pacak K, Grossman AB, Beuschlein F, Reincke M, Hantel C, Zitzmann K, Nölting S.   +21 more
europepmc   +1 more source

Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure

Journal of Parenteral and Enteral Nutrition, 2020
BACKGROUND: Teduglutide reduces or eliminates parenteral support (PS) dependency in patients with short bowel syndrome (SBS). Recent post hoc analyses demonstrated that effects are correlated with baseline PS volume.
Jipan Xie, Palle B. Jeppesen, James Signorovitch   +2 more
exaly   +2 more sources

Quality of Life in Teduglutide-Treated Patients with Short Bowel Syndrome Intestinal Failure—A Nested Matched Pair Real-World Study [PDF]

Nutrients, 2023
Background: Quality of life (QoL) data of chronic intestinal failure (cIF) patients treated with the GLP-2 analogue teduglutide are scarce. This study aims to analyze QoL changes over time in teduglutide-treated patients and compare the results to a ...
Frank Tacke, Ulrich-Frank Pape, Elisabeth Blüthner   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Teduglutide

Reactions Weekly, 2023
  +6 more sources